ArticleMedicine2025
Evaluation of the diagnostic value of combined gastrointestinal endoscopy and serum CEA and CA19-9 levels in gastrointestinal tumor.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroscopy is the gold standard for diagnosing gastrointestinal tumors but has limitations in early tumor detection. Serum biomarkers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are widely used in cancer screening and diagnosis; however, their sensitivity and specificity are often insufficient when used alone. Therefore, combining gastroscopy with serum biomarker testing may improve early diagnostic accuracy. This study aimed to evaluate the diagnostic value of combining gastroscopy with serum CEA and CA19-9 testing for gastrointestinal tumors. This retrospective cohort study included patients who visited our hospital from January 2023 to January 2025 for gastrointestinal diseases and underwent gastroscopy. We applied propensity score matching (PSM) to control for confounding factors, resulting in 60 patients in the experimental group (gastrointestinal malignant tumor group) and 80 patients in the control group (nonmalignant gastrointestinal tumor group). Serum levels of CEA and CA19-9 were measured using chemiluminescent immunoassay. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance of each method and analyze the effectiveness of the combined test. The study found that the combination of gastroscopy with serum CEA and CA19-9 testing significantly increased the diagnostic sensitivity and specificity for gastrointestinal malignant tumors. The sensitivity and specificity for gastroscopy alone were 92.5% and 85.5%, respectively. The sensitivity and specificity for serum CEA and CA19-9 combined testing were 95.0% and 90.0%, respectively. When gastroscopy was combined with serum biomarkers, the diagnostic sensitivity increased to 97.5%, with specificity of 92.5%. Additionally, serum CEA and CA19-9 levels were positively correlated with tumor staging, with levels significantly increasing as tumor stage progressed. This study demonstrates that combining gastroscopy with serum CEA and CA19-9 testing provides significant clinical advantages in diagnosing gastrointestinal tumors. The combined test significantly improves diagnostic sensitivity and specificity, particularly for early screening and tumor staging evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.